---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS301 parts A and B"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: VTS301 parts A and B. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 69 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/vts301-parts-a-and-b"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS301 parts A and B

<a id="heading-3.1.2"></a>

## 3.1.2 VTS301 Parts A and B

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Primary objectives of Parts A and B

> “The primary study objective in Part A was to select the dose of VTS-270 to be used in Part B and Part C.”
> “The primary study objective in Part B is to evaluate, in a double-blind sham-controlled design, the progression of the neurologic manifestations of NPC1 disease following 52 weeks of treatment for subjects treated with VTS-270 compared to sham control, using the following assessments:”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.1-2"></a>

#### Key secondary objective of Part B

> “The key secondary objective for Part B is to evaluate the progression of the neurologic manifestations of NPC1 disease using the total NPC-SS score, excluding the hearing domain and auditory brainstem response (ABR) modifier results, following 52 weeks of treatment for subjects treated with VTS-270 compared to sham controls and the Caregiver CGIC.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Registry statement of purpose

> “This study is to find out how safe and effective VTS-270 is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords).”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.1-4"></a>

#### Objective of the post hoc cerebrospinal fluid biomarker analysis

> “Assess treatment effects of adrabetadex in CSF levels of 24(S)-OHC, calbindin D, and FABP3 over 52 weeks.”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry study dates and enrollment

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-10” |
| Primary completion (actual) | “2018-03-28” |
| Study completion (actual) | “2018-03-28” |
| Enrollment (actual) | “56” |
| Results first posted | “2023-02-22” |

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.2-2"></a>

#### Study sites by country

> “This study has 29 locations”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

| Country | Facility |
| --- | --- |
| United States | “University of Alabama at Birmingham” |
| United States | “Children's Hospital of Orange County” |
| United States | “University of California San Francisco” |
| United States | “University of Colorado Denver” |
| United States | “Shands Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Eunice Kennedy Shriver National Institute of Child Health and Human Development” |
| United States | “Boston Children's Hospital” |
| United States | “Montefiore Medical Center” |
| United States | “University of North Carolina” |
| United States | “Lehigh Valley Health Network” |
| United States | “The Children's Hospital of Philadelphia” |
| United States | “Dell Children's Medical Center of Central Texas” |
| United States | “Multicare Institute for Research and Innovation” |
| Australia | “The Prince of Wales Hospital” |
| Australia | “Monash Medical Centre” |
| Australia | “Royal Melbourne Hospital” |
| Australia | “Royal Perth Hospital” |
| France | “CHU Paris Est - Hospital d'Enfants Armand-Trousseau” |
| Germany | “Katholisches Klinikim Bochum gGmbH” |
| Germany | “Universitaetsklinikum Mainz” |
| Germany | “Universitaetsklinikum Muenster” |
| New Zealand | “Waikato Hospital” |
| Singapore | “National University Hospital (Singapore) Pte, Ltd” |
| Spain | “Hospital Universitario del Valle Hebron” |
| Turkey | “Hacettepe University Medical Faculty” |
| Turkey | “Gazi University Medical Faculty” |
| United Kingdom | “Great Ormond Street Hospital” |
| United Kingdom | “Birmingham Women's and Children's NHS Trust” |

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.2-3"></a>

#### Planned number of sites and regulatory oversight

| Field | Quoted record |
| --- | --- |
| Number of Sites | “Approximately 24 sites worldwide” |

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “The study was regulated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and approved by a central IRB as well as the IRB of each study site.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Multicenter, randomized, double-blind, sham-controlled three-part design

> “This is a multicenter, multinational, prospective, randomized, double-blind, sham-controlled, 3-part, efficacy and safety trial of VTS-270 administered by the lumbar intrathecal (IT) route every 2 weeks, with a planned enrollment of approximately 51 subjects (in Parts A and B) with Niemann-Pick type C1 (NPC1) disease.”
> “Part A evaluated 3 different dose levels of VTS-270 versus sham control, administered as 4 lumbar IT injections every 2 weeks, to determine the dose level for Parts B and C.”
> “Part C will be an open-label extension phase of the study.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.3-2"></a>

#### Label description of Trial 1 Parts A and B

> “Trial 1 Part A/B was a 52-week, double-blind, sham-control trial in 56 patients with NPC who received intrathecal LEMBAZ every 2 weeks for 52 weeks or sham treatment [see Clinical Studies (14)].”
> “Part A and Part B (NCT02534844) included a 52-week, randomized, double-blind, and sham-controlled period and enrolled 56 treatment-naïve patients.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.3-3"></a>

#### Randomization ratios, dose selection, and rescue option

> “In Part A, 12 subjects were randomly assigned to one of four study arms (1:1:1:1), and received either one of three dose levels of adrabetadex (900 mg, 1200 mg, or 1800 mg per IT via LP) or sham procedure (no lumbar puncture).”
> “Following dose selection in Part A, 44 additional subjects were randomized 2:1 to receive either study drug at the dose level chosen in Part A (900 mg) or sham.”
> “Subjects enrolled in Part B who manifested significant disease progression according to predefined clinical criteria after treatment of 26 weeks or more had the option to escape the blinded trial early and enter Part C.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.3-4"></a>

#### Dose selection committee and stratification of Part B randomization

> “Evaluation of hearing loss across the different doses was included as part of the dose selection process.”
> “The goal of the DSC was to select the highest dose with acceptable safety and tolerability to be administered in Parts B and C of the study.”
> “Although randomization in Part B is stratified by miglustat use and baseline NPC‐SS level to ensure balance across the 2 treatment groups, the statistical analyses will not be stratified”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Sham procedure and blinding

> “The sham procedure will consist of 1 to 2 small needle pricks on the lower back at the location where the LP and IT injection is normally made.”
> “The needle(s) will break the skin but no lumbar puncture or needle insertion will occur.”
> “Parents/caregivers will not be present in the room during lumbar IT or sham treatment.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “While it is a double-blind trial, the participant and outcomes assessor will be blinded, as well as the Care Provider and Investigator.”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.3-6"></a>

#### Sponsor rationale for the sham control

> “The sham procedure control (monitored anesthesia care [conscious sedation] or if medically necessary, general anesthesia, and 1 to 2 skin needle pricks) minimizes both undue risk to the NPC1 subjects and the potential for bias.”
> “Subjects enrolled in the VTS301 study were randomly assigned in a 3:1 ratio (in Study Part A) or a 2:1 ratio (in Study Part B) to receive either IT administered VTS-270 or a sham control procedure.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.3-7"></a>

#### Duration of participation in Parts A and B

> “Total duration of subject participation in Parts A and/or B will be approximately 58 weeks, to include a screening period of up to 45 days (maximum), and 52 weeks of serial IT injections or sham control procedures given on a 2-week cycle.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Age, age at neurological onset, and diagnosis

> “Male or female subjects, 4 to 21 years of age at time of screening, with onset of neurological symptoms prior to 15 years of age.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “Trial 1 was a trial in patients aged 4 to 21 years old and with onset of neurological manifestations prior to 15 years old, and included Parts A, B, and C:”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Has confirmed diagnosis of NPC1 determined by either:”
> “two NPC1 mutations”
> “positive filipin staining and at least one NPC1 mutation”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-2"></a>

#### Disease severity required at entry

> “Has an NPC Clinical Severity Scale Score of 1 through 4, inclusive, in two or more of the following components: ambulation, fine motor skills, or swallowing; and has a score of 0 through 4 on the cognition component”
> “Has a total NPC Clinical Severity Scale Score of 10 or greater”
> “Unable to walk, wheelchair dependent (ambulation NPC score=5)”
> “Has need for a nasogastric tube to overcome swallowing difficulties (swallowing NPC score=5) unless used for supplemental feeding or administering medication”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-3"></a>

#### Body weight, prior cyclodextrin, and antipsychotic exclusions

> “Subjects meeting any of the following criteria are to be excluded:”
> “Body weight < 15 kg.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “Has had prior treatment with intravenous 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for NPC1 disease, unless the subject has undergone a minimum 3-month washout period prior to Study Day 0, or has had any prior intrathecal (IT) administration of HP-β-CD”
> “Is taking antipsychotics for treatment of psychosis; use of antipsychotic medication for treatment of other disorders (e.g., Attention Deficit Hyperactivity Disorder) will not exclude participation in this trial”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.4-4"></a>

#### Washout of supplements and investigational treatments

> “Agree to discontinue all nonprescription supplements such as coenzyme Q10, curcumin, cinnamon, fish oil supplements, high-dose vitamin D (> 500 mIU/day), N-acetylcysteine, acetylleucine, or gingko biloba at least 1 month prior to first dose (Study Day 0).”
> “Agree to discontinue any other investigational treatments for NPC including, for example, vorinostat or arimoclomol at least 3 months prior to first dose (Study Day 0).”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Dosage by part in the label

> “In Part A, the LEMBAZ intrathecal dosage was 900 mg every two weeks, 1,200 mg every two weeks (1.3 times the maximum recommended dosage), and 1,800 mg every two weeks (twice the maximum recommended dosage) and in Part B, the LEMBAZ intrathecal dosage was 900 mg every two weeks.”
> “Six patients received at least one dose above 900 mg [see Overdosage (10)].”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.5-2"></a>

#### Dose reduction for drug-related adverse events

> “Subjects who, in the opinion of the investigator, experience a drug-related adverse event (AE) after any blinded IT treatment that is considered clinically relevant and impactful to the subject’s function may have their dose reduced to 600 mg per IT administration for subsequent IT dosing intervals following discussion with the unblinded medical monitor.”
> “If, following dose reduction to 600 mg, a subject continues to experience AEs as described above, the subject’s dose may be further reduced to 400 mg per IT administration for subsequent dosing intervals following discussion with the unblinded medical monitor.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-3"></a>

#### Intrathecal administration procedure

> “The LP and/or sham is to be performed under monitored anesthesia care (conscious sedation) with an appropriate oral or IV agent and performed by an unblinded study physician.”
> “VTS-270 will be administered as an IT slow bolus (1 to 2 minutes, depending on the volume administered) LP injection (maximum rate of administration = 4.5 mL/minute).”
> “Prior to the VTS-270 injection, a volume of CSF fluid approximately equal to the VTS-270 dose is to be removed.”
> “All subjects, sham and study drug, are required to lie flat with feet elevated for 30 to 45 minutes following dosing.”
> “For the 3 days following each procedure, subjects in both the sham and active treatment groups are to avoid acoustic overstimulation and minimize exposure to loud noises, e.g., headphones for music or video games.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Concomitant miglustat

> “If taking miglustat, must have been on a stable dose for the past 6 to 8 weeks and be willing to remain on a stable dose for the duration of participation in Parts A and B of the study.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.5-5"></a>

#### Sham control intervention in the registry

> “No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using the 4-Item NPC Severity Scale Composite Score as a Co-primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Co-primary endpoints: NPC-SS composite score and clinician CGIC at Week 52

> “Change from baseline in NPC-SS composite score at Week 52 in the group treated with VTS-270 vs. the sham control group.”
> “Blinded Clinician CGIC at Week 52 in the group treated with VTS-270 vs the sham control group.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.6.1-2"></a>

##### Scoring of the 4-item composite and the clinician CGIC

> “Each of the four NPC-SS components (ambulation, cognition, fine motor, and swallowing) are rated on a scale from 0 (better) to 5 (worse).”
> “The total score was the sum of individual components scores which ranges from 0 (best) to 20 (worst), with higher scores indicating more severe clinical impairment.”
> “The Investigator rates his/her impression of the change in each participant's condition at week 52 on a scale from marked improvement (1) to marked worsening (7).”

Source: [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)

<a id="topic-3.1.2.6.1-3"></a>

##### Key secondary endpoints as revised in the statistical analysis plan

> “The list of key secondary endpoints in the protocol has been changed to the following:”
> “Change from baseline to Week 52 in the NPC‐SS total score with the hearing domain and ABR modifiers removed”
> “The following key secondary endpoint described in the protocol has been changed to the first other secondary endpoint:”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### Selection of the 4-item composite score for this trial

> “Vtesse, Inc., now a Mallinckrodt Pharmaceuticals company, selected the four-item composite score as the primary efficacy endpoint in the Phase 2/3 multicenter clinical trial of intrathecal adrabetadex in NPC1”
> “The NPC-SS and particularly the 4- and 5-item scales represent key domains identified by families and clinicians as important to quality of life.”
> “All domains were rated except those involving hearing as hearing information was being monitored seperately in the trial to track this as an adverse event, the hearing rating was not part of the efficacy score as the drug can cause hearing loss, and hearing information might have unblinded the NPC-SS raters to treatment status.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.6.1-5"></a>

##### Inter-rater reliability of central NPC-SS scoring in this trial

> “The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.”
> “Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.”
> “The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).”
> “For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).”
> “These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.6.1-6"></a>

##### Development of the NPC clinical severity scale

> “Thus, we developed a clinical severity scale to characterize and quantify disease progression.”
> “Both patient cohorts showed a linear increase in severity scores over time.”

Source: [Yanjanin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2798912/)

<a id="topic-3.1.2.6.1-7"></a>

##### Content validity and meaningful change of the 5-domain scale

> “Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS.”
> “Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.”

Source: [Patterson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7881637/)

<a id="topic-3.1.2.6.1-8"></a>

##### International Delphi consensus on severity scales

> “Consensus was reached (74%) for the 17-domain NPCCSS scale as the first choice in clinical trial settings, but the domains measured in the 5-domain scale should be prioritised as the primary endpoints.”
> “Several scales have been developed and published over the past two decades but, essentially, all are based on a four-domain scale initially developed by Iturriaga et al.”

Source: [Evans et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8600786/)

<a id="topic-3.1.2.6.1-9"></a>

##### Convergent validity of scale domains, including data from this trial

> “Participants were drawn from several studies performed at two sites at which participants with clinically and biochemically confirmed NPC were followed with regular clinical evaluations, including a natural history study for NPC (NCT00344331), a phase 1/2a trial of intrathecal 2-hydroxypropyl-beta-cyclodextrin (adrabetadex, NCT01747135), a phase 2b/3 trial of adrabetadex (NCT02534844), and an expanded access program for treatment of NPC with adrabetadex (IND119856).”
> “The 5DNPCCSS domains were significantly related in the expected directions to their respective direct assessments, supporting their construct validity.”
> “In the years since its publication, researchers and regulators have noted that the wide-ranging composition of the NPC-CSS-17, meant to capture the full range of clinical presentation, might reduce its ability to detect an effect of intervention.”

Source: [Farmer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12353886/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size and its basis

> “The sample size was determined based on the potential number of available subjects for this ultra-rare disorder.”
> “Based on the comparison of the NIH phase 1 subjects and similar subjects in the NIH natural history data set, approximately 51 subjects, 16 on sham and 35 on active treatment, will allow for the detection of clinically relevant difference of the sum of the 4 NPC-SS score domains that make up the composite outcome.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

##### Power calculation assumptions

> “The VTS‐270 group has an average increase in value over 52 weeks ranging from 0 points to 0.2 points.”
> “The sham group has an average increase in value over 52 weeks ranging from 1.6 points to 1.9 points.”
> “Based on these assumptions, an analysis of covariance (ANCOVA) will have 79% power to detect a statistically significant difference between the VTS‐270 and sham groups.”
> “Three additional subjects above the planned sample size were enrolled into the study, such that there were 54 subjects randomized.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants analyzed for the co-primary endpoints

| Analysis | Sham control | Adrabetadex |
| --- | --- | --- |
| 4-item NPC-SS composite, participants analyzed | “18” | “38” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants analyzed for secondary endpoints

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| NPC-SS total score excluding hearing and ABR | “18” | “37” |
| Annualized rate of change (slope) of NPC-SS composite | “14” | “34” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Analysis populations in the protocol

> “The modified intent-to-treat (mITT) population will consist of all randomized subjects who received at least one dose of VTS-270 infusion or sham control.”
> “The primary population for the primary efficacy assessment will be the mITT.”
> “The per-protocol (PP) population will consist of all randomized subjects who had no major protocol deviation that would have had an impact on the primary outcome and who received at least 75% of their scheduled VTS-270 IT administrations.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.7.2-2"></a>

##### Modified intent-to-treat population as defined in the statistical analysis plan

> “The modified intent‐to‐treat (mITT) population will consist of all randomized subjects in Parts A and B who received at least one dose of 900 mg of VTS‐270 infusion or sham control.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Analysis populations in the registry results

> “mITT population included all randomized participants who received at least one treatment (sham or adrabetadex).”
> “Safety population was defined as all randomized participants who received at least 1 procedure (adrabetadex infusion via LP or sham).”

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

##### Primary analysis method and handling of missing data

> “To protect against the potential bias that may occur if outcomes for the completers are different from those for the non‐completers (i.e., missing not at random; MNAR), the approach taken will be to impute all missing observations from either treatment arm as if they came from the sham group.”
> “An ANCOVA, with treatment group, study part, and baseline NPC‐SS composite score included in the model, will be performed to test for differences in the change from baseline to Week 52 between VTS‐270 and sham groups in the co‐primary efficacy outcome measure.”
> “Considering the small sample size, this ANCOVA will be performed using a nonparametric approach such that the outcome data will be ranked.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="topic-3.1.2.7.2-5"></a>

##### Clinician CGIC analysis and hierarchical testing of key secondary endpoints

> “The analysis of the blinded Clinician CGIC at Week 52 will be conducted using the nonparametric Van Elteren method to test for the treatment effect using study part as a blocking variable.”
> “The following key secondary endpoints comparing subjects treated with VTS-270 with the sham controls will be analyzed using a hierarchical testing, serial gatekeeping strategy based on the mITT population.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.7.2-6"></a>

##### Statistical methods of the post hoc biomarker analysis

> “Wilcoxon signed-rank test was used to assess within-group changes in CSF biomarkers from baseline to Week 52 (SAS v9.4).”
> “Nominal statistical significance was defined as P<0.05 without adjustment for multiplicity”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participant flow in the ClinicalTrials.gov record

| Milestone | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- | --- | --- | --- | --- |
| Started | “3” | “3” | “3” | “3” | “29” | “15” |
| Completed | “3” | “3” | “3” | “3” | “27” | “14” |
| Not completed | “0” | “0” | “0” | “0” | “2” | “1” |
| Withdrawal by subject | “0” | “0” | “0” | “0” | “2” | “1” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

##### Discontinuations due to adverse events

> “No participants discontinued the study due to treatment-emergent adverse events (TEAEs) in Part A/B of VTS301.”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record

| Characteristic | Sham control (n = 18) | Adrabetadex (n = 38) | Total (n = 56) |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “11.7(5.10)” | “12.7(5.64)” | “12.4(5.45)” |
| Female | “10” | “16” | “26” |
| Male | “8” | “22” | “30” |
| White | “16” | “31” | “47” |
| Asian | “1” | “4” | “5” |
| Hispanic or Latino | “3” | “3” | “6” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

##### Baseline 4-item NPC-SS composite score

| Statistic | Sham control | Adrabetadex |
| --- | --- | --- |
| Baseline mean | “8.1” | “8.8” |
| Baseline standard deviation | “4.27” | “3.12” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.2-3"></a>

##### Baseline weight, miglustat use, seizures, symptom duration, and total severity score

| Characteristic | Adrabetadex (N=38) | Sham control (N=18) |
| --- | --- | --- |
| Weight (kg), mean (SD) | “48.1 (25.27)” | “40.2 (18.98)” |
| Miglustat use, n (%) | “25 (66)” | “9 (50)” |
| Seizures, n (%) | “15 (39)” | “5 (28)” |
| Duration of neurologic symptoms (years), mean (SD) | “7.1 (4.15)” | “5.9 (5.16)” |
| Baseline NPC-CSS total score (minus hearing/ABR), mean (SD) | “17.8 (6.48)” | “16.9 (8.16)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.2.8.2-4"></a>

##### Label demographics of participants receiving up to 900 mg and sham

> “There were 32 patients who received up to 900 mg in the LEMBAZ treatment group and 18 in the sham-control group with a mean age of 12 years old (minimum age 4, maximum age 22).”
> “Patients in Trial 1 were 24 female (48%), 26 male (52%).”
> “Twenty-eight patients (56%) experienced neurological symptom onset at <6 years of age.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.2.8.2-5"></a>

##### Cerebrospinal fluid biomarker analysis subset

> “This biomarker study included 34 participants (Table 1), with a mean age of 12.8 years and mean age at neurological onset of 5.7 years”
> “About two-thirds were also receiving miglustat”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Co-primary endpoint: change in 4-item NPC-SS composite score at Week 52

| Statistic | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| Change from baseline at Week 52, mean | “-0.1” | “0.0” |
| Change from baseline at Week 52, standard deviation | “1.55” | “2.45” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-2"></a>

##### Co-primary endpoint: clinician CGIC at Week 52

| CGIC category | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| Markedly improved (1) | “0” | “0” |
| Moderately improved (2) | “1” | “5” |
| Minimally improved (3) | “4” | “9” |
| Unchanged (4) | “9” | “16” |
| Minimally worse (5) | “2” | “6” |
| Moderately worse (6) | “2” | “1” |
| Markedly worse (7) | “0” | “1” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-3"></a>

##### Sponsor statements of the Parts A and B result

> “The results of the Company’s recently completed registration trial for the product did not show a statistically significant separation from placebo.”
> “Neither the VTS-270 nor the placebo arm showed disease progression as would be expected for a neurodegenerative condition over 52 weeks of observation.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

> “Analysis of data from Part A/B of this study shows no benefit of adrabetadex on the pre-specified co-primary endpoints.”
> “For those subjects who appear to benefit from treatment, the investigator must review with them the risks associated with intrathecal adrabetadex, including hearing loss, and the data from the randomized, controlled trial that demonstrated no significant differences between patients treated with adrabetadex and sham-treated subjects on any efficacy measures.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.8.3-4"></a>

##### Post hoc analysis by miglustat use

> “A post-hoc analysis evaluating the effect of miglustat use showed that subjects receiving miglustat (with or without adrabetadex) show evidence of disease stabilization but subjects receiving adrabetadex without miglustat show disease worsening comparable to sham subjects not on miglustat.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.2.8.3-5"></a>

##### Secondary endpoints reported in the ClinicalTrials.gov results

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD) | “-0.74(2.357)” | “-0.34(4.226)” |
| Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants | “13” | “22” |
| Participants who qualified for the rescue option | “2” | “2” |
| Time to one-point worsening in NPC-SS composite score, median days (95% CI) | “118 (55 to 364)” | “169 (70 to 278)” |
| 9-Hole Peg Test, change at Week 52, seconds, mean (SD) | “-1.49(15.958)” | “-1.79(34.760)” |
| Annualized rate of change (slope) of NPC-SS composite, mean (SD) | “-0.05(1.640)” | “0.08(2.441)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.3-6"></a>

##### Timed Up and Go test and total NPC-SS including hearing

| Outcome measure | Sham control | Adrabetadex |
| --- | --- | --- |
| Timed Up and Go, change at Week 52, seconds, mean | “0.86” | “2.70” |
| Timed Up and Go, change at Week 52, seconds, SD | “19.232” | “9.633” |
| Total NPC-SS with hearing and ABR, change at Week 52, mean | “0.000” | “0.75” |
| Total NPC-SS with hearing and ABR, change at Week 52, SD | “1.000” | “4.500” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-7"></a>

##### Change in each NPC-SS domain at Week 52

| Domain, change from baseline at Week 52 | Sham control, mean | Sham control, SD | Adrabetadex, mean | Adrabetadex, SD |
| --- | --- | --- | --- | --- |
| Ambulation | “0.00” | “0.679” | “0.06” | “1.434” |
| Fine motor | “0.07” | “0.917” | “0.24” | “1.103” |
| Cognition | “-0.14” | “0.663” | “0.06” | “0.919” |
| Swallowing | “0.00” | “1.109” | “-0.29” | “1.360” |
| Memory | “0.00” | “0.784” | “0.18” | “1.218” |
| Speech | “0.14” | “0.663” | “-0.18” | “0.673” |
| Eye movement | “0.00” | “0.679” | “-0.06” | “0.547” |
| Hearing | “-0.22” | “1.302” | “1.14” | “1.236” |
| Seizures | “-0.50” | “1.286” | “-0.06” | “0.952” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.3-8"></a>

##### Post hoc cerebrospinal fluid biomarkers at Week 52 in adrabetadex-treated participants

> “At 52 weeks of treatment, nominally statistically significant increases in CSF 24(S)-OHC (27.7%; Figure 3) were observed, indicating adrabetadex increases neuronal cholesterol trafficking”
> “In addition, we observed nominally significant decreases in CSF levels of calbindin D (18.3%; Figure 4) and FABP3 (40.5%; Figure 5) over the same period”
> “27.7% increase from baseline at 52 weeks n=22 IQR (6.5%, 54.2%) P=0.0012”
> “18.3% decrease from baseline at 52 weeks n=24 IQR, –30.0%, 3.8% P=0.0117”
> “40.5% decrease from baseline at 52 weeks n=24 IQR, –69.4%, 0.0% P=0.0079”

Source: [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)

> “Results from a biomarker analysis of cerebrospinal fluid (CSF) samples banked during a previously completed Phase 2b/3 clinical trial show that adrabetadex addresses the core pathology of NPC and is associated with reductions in biomarkers of neuronal damage and cell death.”

Source: [Mandos Health survival and biomarker analyses press release (2025)](https://www.berentx.com/news/adrabetadex-data-analyses-show-benefit-npc/)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### EQ-5D-3L visual analog scale at baseline and Week 52

| Time point | Sham control mean | Sham control SD | Adrabetadex mean | Adrabetadex SD |
| --- | --- | --- | --- | --- |
| Baseline | “71.9” | “16.28” | “68.3” | “19.97” |
| Week 52 | “73.2” | “13.04” | “75.7” | “19.00” |

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)

<a id="topic-3.1.2.8.4-2"></a>

##### Caregiver-rated CGIC responders at Week 52

> “CGIC Responders are defined as participants who received the caregiver's rating of no change, minimally improved, moderately improved, or markedly improved from baseline to Week 52.”

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

| Outcome | Sham control (n = 18) | Adrabetadex (n = 38) |
| --- | --- | --- |
| CGIC responders at Week 52, participants | “7” | “23” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Deaths, serious adverse events, and other adverse events by arm

| Event | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- | --- | --- | --- | --- |
| All-cause mortality | “0/3 (0.00%)” | “0/3 (0.00%)” | “1/3 (33.33%)” | “0/3 (0.00%)” | “0/29 (0.00%)” | “1/15 (6.67%)” |
| Any serious adverse event | “1/3 (33.33%)” | “0/3 (0.00%)” | “2/3 (66.67%)” | “0/3 (0.00%)” | “16/29 (55.17%)” | “3/15 (20.00%)” |
| Any other (non-serious) adverse event | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “28/29 (96.55%)” | “14/15 (93.33%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-2"></a>

##### Serious adverse events of hearing, seizure, and aspiration in Part B

| Serious adverse event | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- |
| Deafness | “3/29 (10.34%)” | “0/15 (0.00%)” |
| Hearing impaired | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Seizure | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Aspiration | “2/29 (6.90%)” | “1/15 (6.67%)” |
| Pneumonia aspiration | “3/29 (10.34%)” | “0/15 (0.00%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

##### Common non-serious adverse events in Part B

| Adverse event | Part B adrabetadex 900 mg | Part B sham |
| --- | --- | --- |
| Vomiting | “15/29 (51.72%)” | “2/15 (13.33%)” |
| Back pain | “14/29 (48.28%)” | “0/15 (0.00%)” |
| Fatigue | “12/29 (41.38%)” | “2/15 (13.33%)” |
| Pyrexia | “12/29 (41.38%)” | “3/15 (20.00%)” |
| Gait disturbance | “11/29 (37.93%)” | “2/15 (13.33%)” |
| Hypoacusis | “10/29 (34.48%)” | “0/15 (0.00%)” |
| Fall | “10/29 (34.48%)” | “1/15 (6.67%)” |
| Diarrhoea | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Headache | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Hearing impaired | “8/29 (27.59%)” | “6/15 (40.00%)” |
| Nausea | “8/29 (27.59%)” | “0/15 (0.00%)” |
| Ataxia | “7/29 (24.14%)” | “2/15 (13.33%)” |
| Tinnitus | “5/29 (17.24%)” | “0/15 (0.00%)” |

Source: [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

##### Company summary of safety in the Parts A and B safety population

| Event | Adrabetadex (n=38) | Sham control (n=18) |
| --- | --- | --- |
| Any TEAE, n (%) | “38 (100)” | “17 (94)” |
| Non-fatal treatment-emergent SAE, n (%) | “20 (53)” | “4 (22)” |
| Hearing impaired, serious, n (%) | “4 (11)” | “1 (6)” |
| Pneumonia, aspiration, serious, n (%) | “4 (11)” | “1 (6)” |
| Deafness, serious, n (%) | “3 (8)” | “0 (0)” |

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

> “Adverse events with ≥30% higher incidence in the adrabetadex-treated vs sham group included vomiting, hypoacusis, back pain, diarrhea, gait disturbance, and fatigue; treatment-related events with ≥30% higher incidence were vomiting, hypoacusis, back pain, and fatigue (Supplemental Table 3).”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: design limitations of Parts A and B

- Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
- Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
- Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
- Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
- Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
- Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
- Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
- Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
- Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.

Source: [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844); [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results); [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844); [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf); [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf); [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf); [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741); [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

<a id="topic-3.1.2.9-2"></a>

#### Little progression in the sham group

> “A phase 2b/3 one year sham controlled trial failed to show benefit as the sham group had little progression.”
> “In NPC, placebo/sham-controlled trials are highly challenging due to variability of the disease”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-3.1.2.9-3"></a>

#### Sponsor review of data quality after the result

> “The Company is in the process of evaluating this portion of the study in order to ensure the data was properly captured and of the highest quality.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-3.1.2.9-4"></a>

#### Two central raters

> “Limitations of this study include use of only two raters generating the NPC-SS scores.”

Source: [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)

<a id="topic-3.1.2.9-5"></a>

#### No cerebrospinal fluid collection from sham-treated participants

> “Collect cerebrospinal fluid (CSF), urine, and plasma samples from the subjects receiving study drug, and urine and plasma samples from subjects randomized to sham control, will be collected at prespecified intervals and stored for exploratory biomarker analyses.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.2.9-6"></a>

#### Planned trial manuscript, May 2022

> “We are in the midst of putting together a manuscript for publication summarizing the data and experience from the VTS-301 trial, which we recognize as an important part of advancing understanding of the trial, of adrabetadex*, and of NPC1.”

Source: [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
